Floatz logo

LEUPROLIDE

Polycystic Ovary Syndrome

Assiut Universityprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Polycystic Ovary Syndrome cohort.

Asset / SponsorPhaseRating
Liraglutide
Peking University Third Hospital
Phase 4BBB
Semaglutide
Methodist Health System
Phase 4BBB
Hcg
Eman Basuni Ebrahim Mowad
Phase 4BBB
Drospirenone
Ege University
Phase 4BBB
FOLLITROPIN BETA
Universitair Ziekenhuis Brussel
Phase 4BBB

View all 50 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →